Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy | Zendy

C. Andréjak | Zendy; Deepak V. Almeida | Zendy; Sandeep Tyagi | Zendy; Paul J. Converse | Zendy; Nicole C. Ammerman | Zendy; J Grosset | Zendy

Open Access

Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy

Author(s) -

C. Andréjak,

Deepak V. Almeida,

Sandeep Tyagi,

Paul J. Converse,

Nicole C. Ammerman,

J Grosset

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks421

Subject(s) - moxifloxacin , ethambutol , clarithromycin , rifampicin , in vivo , medicine , rifapentine , pharmacology , rifamycin , isoniazid , microbiology and biotechnology , antibiotics , mycobacterium tuberculosis , biology , tuberculosis , pathology , latent tuberculosis

Mycobacterium xenopi is a common agent of non-tuberculous mycobacterial lung diseases in Europe. However, an optimal treatment regimen for M. xenopi infection has not yet been established. Appropriate in vitro and in vivo model systems are needed for characterization of the activity of potential drugs and drug combinations against M. xenopi.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research